ReviewOxidative medicine and cellular longevity2016
Endogenous Sulfur Dioxide: A New Member of Gasotransmitter Family in the Cardiovascular System.
Review in Oxidative medicine and cellular longevity, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 158 citations in OpenAlex.
- Toxic Effects of Sulfur Dioxide: A Review.Toxics · 2026Review
- Advances in Coumarin Fluorescent Probes for Medical Diagnostics: A Review of Recent Developments.Biosensors · 2026Review
- The Yin-Yang of sulfur dioxide: Effect on cognitive function.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- Gasotransmitters in Modern Medicine: Promises and Challenges in the Use of Porous Crystalline Carriers.Advanced healthcare materials · 2025Review
- Sulfur Dioxide Alleviates Organ Damage and Inflammatory Response in Cecal Ligation and Puncture-Induced Sepsis Rat.Molecular biotechnology · 2025Article
- Harnessing Gasotransmitters to Combat Age-Related Oxidative Stress in Smooth Muscle and Endothelial Cells.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Nonlinear amplification of nano bowl surface concavity on the critical response threshold to biosignals.Nature communications · 2024Article
- Gasotransmitters and noble gases in cardioprotection: unraveling molecular pathways for future therapeutic strategies.Basic research in cardiology · 2024Review
- Sulfenylation of ERK1/2: A novel mechanism for SOHeliyon · 2024Article
- Recent Progress in Polyion Complex Nanoparticles with Enhanced Stability for Drug Delivery.Polymers · 2024Review
- Electrochemical Detection of Gasotransmitters: Status and Roadmap.ACS sensors · 2024Review
- Elucidating the Molecular Pathways and Therapeutic Interventions of Gaseous Mediators in the Context of Fibrosis.Antioxidants (Basel, Switzerland) · 2024Review
- Effects of gas signaling molecule SOThe Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2024Article
- A rationally designed fluorescent probe for sulfur dioxide and its derivatives: applications in food analysis and bioimaging.Analytical and bioanalytical chemistry · 2024Article
- The Role of Gasotransmitter-Dependent Signaling Mechanisms in Apoptotic Cell Death in Cardiovascular, Rheumatic, Kidney, and Neurodegenerative Diseases and Mental Disorders.International journal of molecular sciences · 2023Review
- Cyclodextrin Metal-Organic Framework as a Broad-Spectrum Potential Delivery Vehicle for the Gasotransmitters.Molecules (Basel, Switzerland) · 2023Article
- Advances in the research of sulfur dioxide and pulmonary hypertension.Frontiers in pharmacology · 2023Review
- Elucidating the role of circNFIB in myocardial fibrosis alleviation by endogenous sulfur dioxide.BMC cardiovascular disorders · 2022Article
- Therapeutic gas-releasing nanomedicines with controlled release: Advances and perspectives.Exploration (Beijing, China) · 2022Review
- A Whiff of Sulfur: One Wind a Day Keeps the Doctor Away.Antioxidants (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sulfur dioxide (SO2) was previously regarded as a toxic gas in atmospheric pollutants. But it has been found to be endogenously generated from metabolism of sulfur-containing amino acids in mammals through transamination by aspartate aminotransferase (AAT). SO2 could be produced in cardiovascular tissues catalyzed by its synthase AAT. In recent years, studies revealed that SO2 had physiological effects on the cardiovascular system, including vasorelaxation and cardiac function regulation. In addition, the pathophysiological effects of SO2 were also determined. For example, SO2 ameliorated systemic hypertension and pulmonary hypertension, prevented the development of atherosclerosis, and protected against myocardial ischemia-reperfusion (I/R) injury and isoproterenol-induced myocardial injury. These findings suggested that endogenous SO2 was a novel gasotransmitter in the cardiovascular system and provided a new therapy target for cardiovascular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.